Regenerative medicine company developing autologous cell therapies.
RepliCel Life Sciences Inc. is leading a revolution in the development of products for sports medicine and aesthetics.
We are a regenerative medicine company developing innovative, clinical-stage technologies for unparalleled skin rejuvenation, tendon regeneration, and hair regrowth.
RepliCel is currently involved in three clinical development programs: RCT-01 for treatment of Achilles tendinosis, RCS-01 for skin rejuvenation, and RCH-01 for treatment of Androgenic Alopecia.
In Asia, RCH-01 is the subject of a co-development partnership with cosmetics and skincare giant Shiseido Company, Limited. Shiseido is currently funding a clinical study for the treatment of male and female pattern baldness (androgenic alopecia) in Japan with data anticipated in late 2018.
Visit website: https://www.replicel.com/
People at RepliCel
RepliCel contracts Accerise to plan phase 2 cell therapy trials in Japan
Biospace - 19-May-2021
Successful trial results could bring us skin rejuvenation & tendon regeneration productsRead more...
Interview with regenerative medicine RepliCel’s CEO
Digital Journal - 21-Sep-2017
Regenerative medicine is a game-changing area of medicine. It has the potential to fully heal dam...Read more...